Next Article in Journal
Advances in the Systemic Treatment of Triple-Negative Breast Cancer
Previous Article in Journal
Clinical Application and Utility of Genomic Assays in Early-Stage Breast Cancer: Key Lessons Learned to Date
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue s1
10.3747/co.25.4000
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines

by
A. Matutino
1,
A.A. Joy
2,
C. Brezden-Masley
3,
S. Chia
4 and
S. Verma
1,*
1
Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 29th Street NW, Calgary, AB T2N 4N2, Canada
2
Department of Oncology, Division of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
3
Department of Oncology, St. Michael’s Hospital, Toronto, ON, Canada
4
Department of Oncology, BC Cancer, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(s1), 131-141; https://doi.org/10.3747/co.25.4000
Submission received: 2 March 2018 / Revised: 4 April 2018 / Accepted: 7 May 2018 / Published: 1 June 2018

Abstract

Estrogen receptor modulators and estrogen deprivation have become standards of care for hormone receptor– positive metastatic breast cancer. However, after traditional first-line endocrine monotherapy treatment, the disease typically progresses despite the initial high rate of clinical benefit. Multiple studies have aimed at optimizing treatment strategies to improve upon clinical benefit beyond the traditional single-agent endocrine treatment. With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit. In this review, we present treatment options clinically relevant to the management of hormone-positive, her2-negative metastatic breast cancer, and we propose a treatment algorithm based on the current literature.
Keywords: antineoplastic agents; hormonal therapy; combined chemotherapy protocols; breast neoplasms; drug therapy; metastasis antineoplastic agents; hormonal therapy; combined chemotherapy protocols; breast neoplasms; drug therapy; metastasis

Share and Cite

MDPI and ACS Style

Matutino, A.; Joy, A.A.; Brezden-Masley, C.; Chia, S.; Verma, S. Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Curr. Oncol. 2018, 25, 131-141. https://doi.org/10.3747/co.25.4000

AMA Style

Matutino A, Joy AA, Brezden-Masley C, Chia S, Verma S. Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology. 2018; 25(s1):131-141. https://doi.org/10.3747/co.25.4000

Chicago/Turabian Style

Matutino, A., A.A. Joy, C. Brezden-Masley, S. Chia, and S. Verma. 2018. "Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines" Current Oncology 25, no. s1: 131-141. https://doi.org/10.3747/co.25.4000

APA Style

Matutino, A., Joy, A. A., Brezden-Masley, C., Chia, S., & Verma, S. (2018). Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology, 25(s1), 131-141. https://doi.org/10.3747/co.25.4000

Article Metrics

Back to TopTop